|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 218.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.58 mL||22.91 mL||45.82 mL|
|5 mM||0.92 mL||4.58 mL||9.16 mL|
|10 mM||0.46 mL||2.29 mL||4.58 mL|
|50 mM||0.09 mL||0.46 mL||0.92 mL|
References are publications that support the products' biological activity.
If you know of a relevant reference for Propranolol glycol, please let us know.
View Related Products by Product Action
Keywords: Propranolol glycol, supplier, Propranolol, metabolite, β-adrenoceptor, beta-adrenoceptor, b-adrenoceptor, β-adrenergic, beta-adrenergic, b-adrenergic, Receptors, Non-Selective, antagonists, blockers, Non-selective, Adrenergic, Beta, Receptors, Non-selective, Adrenergic, Beta, Receptors, Tocris Bioscience
Citations for Propranolol glycol
Citations are publications that use Tocris products.
Currently there are no citations for Propranolol glycol. Do you know of a great paper that uses Propranolol glycol from Tocris? If so please let us know.
Reviews for Propranolol glycol
There are currently no reviews for this product. Be the first to review Propranolol glycol and earn rewards!
Have you used Propranolol glycol?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.